A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Intestinal alkaline phosphatase at the crossroad of intestinal helath and disease - a putative role in type 1 diabetes
Tekijät: M. I. Lassenius, C. L. Fogarty, M. Blaut, K. Haimila, L. Riittinen, A. Paju, J. Kirveskari, J. Järvelä, A. J. Ahola, D. Gordin, M.-A. Härma, A. Kumar, S. R. Hamarneh, R. A. Hodin, T. Sorsa, T. Tervahartiala, S. Hörkkö, P. J. Pussinen, C. Forsblom, M. Jauhiainen, M.-R. Taskinen, P.-H. Groop, M. Lehto; and on behalf of the FinnDiane Study Group
Julkaisuvuosi: 2017
Journal: Journal of Internal Medicine
Vuosikerta: 281
Numero: 6
Aloitussivu: 586
Lopetussivu: 600
Sivujen määrä: 15
ISSN: 0954-6820
DOI: https://doi.org/10.1111/joim.12607
Conclusion
Deprivation of protective intestinal factors may increase the risk of inflammation in the gut – a phenomenon that seems to be present already in patients with uncomplicated type 1 diabetes. Low levels of intestinal IgA and antibodies to oxidized lipid epitopes may predispose such patients to inflammation-driven complications such as cardiovascular disease and diabetic nephropathy. Importantly, oral IAP supplementation could have beneficial therapeutic effects on gut metabolic homeostasis, possibly through stimulation of intestinal IgA secretion.
